medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2014, Number 1

<< Back

Rev Biomed 2014; 25 (1)

Strategies for generate influenza vaccines generation

Romero-Beltrán L, Ayora-Talavera G

Language: Spanish
References: 35
Page: 39-45
PDF size: 221.83 Kb.


ABSTRACT

Influenza viruses cause anual epidemics and ocassional pandemics, making them responsable for aproximately 300,000 anual deaths. Treatment options are limited and the development of resistant strains have forced us to take action to prevent the disease. Currently there are attenuated and inactivated virus vaccines generated from egg cultures, even though the new tendency is to use cellular cultures that allow us to obtain vaccines quicker and in more quantities. The use of techniques as reverse genetics allows the development of adapted recombinant virus vaccines. This paper aims to describe the influenza virus characteristics, immunology, vaccines options and the future of the development of influenza virus vaccines.


REFERENCES

  1. Organización mundial de la salud. (Consultado 10 febrero 2014) disponible en URL: http://www.who.int/ mediacentre/factsheets/fs211/es/index.html.

  2. Martin, M, Hans, WD, Jindrich, CJ. Novel swineorigin influenza A virus in humans: another pandemic knocking at the door. Med Microbiol Immunol. 2009 Ago; 198 (3): 175-183.

  3. Lambert, LC, Fauci, AS. Influenza vaccines for the future. NEJM. 2010 Nov; 363 (21): 2036-2044.

  4. Dormitzer, PR, Tsai, TF, Del Giudice, G. New technologies for influenza vaccines. Human Vaccines & Immunotherapeutics. 2012 Ene; 8 (1): 45–58.

  5. Bhoumik, P, Hughes, AL. Reassortment of ancient neuraminidase and recent hemagglutinin in pandemic (H1N1) 2009 virus. Emerg Infect Dis. 2010 Nov; 16 (11): 1-7.

  6. Vega, BRS, Reyes-Terán, G. El virus de la influenza. Nct. 2007 Mar; 66 (Suppl 1): 12-14.

  7. Talledo, M, Zumaeta, K. Los virus Influenza y la nueva pandemia A/H1N1. Rev Peru Biol. 2009 Dic; 16(2): 227-238.

  8. Vaqué, RJ, Gil, CJ, Brotons, AM. Principales características de la pandemia por el nuevo virus influenza A (H1N1). Med Clin (Barc). 2009 Oct; 133(13): 513-521.

  9. Tong, S, Zhu, X, Li, Y, Shi, M, Zhang, J, Bourgeois, M, et al. New world bats harbour diverse influenza A viruses. PLoS pathog. 2013 Oct; 9 (10):1003657.

  10. Rovid, SA. Influenza. The Center for food security and public health. Iowa State University. Technical Fact sheet. 2010 Jan; .1-46. Tomado de: (http://www. cfsph.iastate.edu/Factsheets/pdfs/influenza.pdf), accesado el 10 de julio de 2013.

  11. Medina, RA, Garcia-Sastre, A. Influenza A viruses: new research developments. Nat rev micro. 2011 Ago; 9 (8): 590-603.

  12. Belshe, RB. The Origins of Pandemic Influenza- Lessons from the 1918 Virus. N Engl J Med. 2005 Nov; 353 (21): 2209-2211.

  13. Dawood, SF, Jain, S, Finelly, L, Shaw, MW, Lindstrom, S, Garten, RJ, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009 Jun; 360 (25): 2605-15.

  14. Agencia noticiosa CNN, tomado de: (http://mexico. cnn.com/salud/2010/08/10/la-oms-anuncia-el-fin-dela- pandemia-por-ah1n1-despues-de-14-meses) 2010, accesado el 30 de abril de 2012.

  15. Secretaria de salud. Tomado de: http://portal.salud. gob.mx/contenidos/noticias/influenza/estadisticas. html. 2009. Accesado el 20 de mayo de 2012.

  16. Piñón-Ramos, A, Oropesa-Fernández, S, Aragonés-López, C, Galindo, B, Acosta-Herrera, B, Hernández-Espinosa, B. Influenza y vacunación. Rev Biomed. 2005 Ene; 16 (1): 45-53.

  17. Bridges, CB, Fakunda, K, Uyeki, TM, Cox, NJ, Singleton, JA. Prevention and control of influenza. Recommendations of the advisory committee on immunization practice (ACIP). MMWR. 2002 Feb; 51(3): 1-36.

  18. Gubareva, LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus res. 2004 Jul; 103 (1): 199-203.

  19. Democratis, J, Pareek, M, Stephenson, I. Use of neuraminidase inhibitors to combat pandemic influenza. J. Antimicrob. Chemother. 2006 Sep. 58 (5): 911-915.

  20. Moscona, A. Neuraminidase Inhibitors for Influenza. N Engl J Med. 2005 Sep; 353 (13): 1363-73.

  21. Tanaka, T, Nakajima, K, Murashima, A, Garcia- Bournissen, F, Koren, G, Ito, S. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. Cmaj. 2009 Jul; 181 (1): 55-58.

  22. Newmann, G, Noda, T, Kawaoka, Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature. 2009 Jun; 459 (7249): 931-939.

  23. Wang, JP, Bowen, GN, Padden, C, Cerny, A, Finberg, RW, Newburger, PE, et al. Toll-like receptor–mediated activation of neutrophils by influenzaAvirus Phagocytes. 2008 Sep; 112(5): 2028- 2034.

  24. Sanderson, SD, Thoman, ML, Kis, K, Virts, EL, Herrera, EB. Innate Immune Induction and Influenza Protection Elicited by a Response-Selective Agonist of Human C5a. PLoS ONE. 2012 Jul; 7(7): e40303.

  25. Hashimoto, Y, Moki, T, Takizawa, T, Shiratsuchi, A, Nakanishi, Y. Evidence for Phagocytosis of Influenza Virus-Infected, Apoptotic Cells by Neutrophils and Macrophages in Mice. The Journal of Immunology. 2007 Feb; 178(4): 2448-2457.

  26. Lee, N, Wong, CK, Chan, PKS, Chan, MCW, Wong, RYK. Cytokine Response Patterns in Severe Pandemic 2009 H1N1 and Seasonal Influenza among Hospitalized Adults. PLoS ONE. 2011 Oct; 6(10): e26050.

  27. Lee, HY, Topham, DJ, Park, Y, Hollenbaugh, J, Treanor, J, Mosmann, TR, et al. Simulation and Prediction of the Adaptive Immune Response to Influenza A Virus Infection. J. Virol. 2009 Jul; 83 (14): 7151-7165.

  28. Liu, Y, Wu, Y, Lam, KT, Lee, PPW, Tu, W, Lau. YL. Dendritic and T Cell Response to Influenza is Normal in the Patients with X-Linked Agammaglobulinemia. J Clin Immunol. 2012 Jun; 32 (3):421–429.

  29. Jung, EJ, Lee, KH, Seong, BL. Reverse genetic platform for inactivated and live-attenuated influenza vaccine. Experimental and molecular medicine. 2010 Feb; 42 (2): 116-121.

  30. Cargnelutti, DE, Sánchez, MV, Mattion, NM, Scodeller, EA. Development of a universal CTLbased vaccine for influenza. Bioengineered. 2013 Ene; 4 (6): 1-5.

  31. Shaw, A. New technologies for new influenza vaccines. Vaccine. 2012 Jul; 30(33): 4927-4933.

  32. Reisinger, KS, Block, SL, Izu, A, Groth, N, Holmes, SJ. Subunit Influenza Vaccines Produced from Cell Culture or in Embryonated Chicken Eggs: Comparison of Safety, Reactogenicity, and Immunogenicity. JID. 2009 Sep; 200 (6):849–857.

  33. Caubet, JC, Wang, J. Current understanding of egg allergy. Pediatr Clin North Am. 2011 Abr; 58(2): 427-443.

  34. Galarza, JM, Latham, T, Cupo, A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral immunol. 2005 Mar; 18(1): 244-251.

  35. Baker, SF, Guo, H, Albrecht, RA, Garcia-Sastre, A, Topham, DJ, Martinez-Sobrido, L. Protection against lethal influenza with a viral mimic. JVI. 2013 Ago; 1(8): 8591-8605.




2020     |     www.medigraphic.com